Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players√Ę‚ā¨‚ĄĘ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst

Bleeding Disorders Treatment Market by Type (Hemophilia A, Hemophilia B, and Others), Drug Class (Plasma-Derived Coagulation Factor Concentrates Market and Others), Treatment (Desmopressin, Hormone Replacement Therapy), and Region-Forecast till 2030


ID: MRFR/Pharma/5129-HCR | 85 Pages | Author: Rahul Gotadki| April 2024

Bleeding Disorders Treatment Market Scenario


The Bleeding Disorders Treatment Market is expected to reach USD 29.8 billion at CAGR 10.7% during the forecast period (2022‚Äď2030).


A bleeding disorder is a condition where there is a problem with the body’s clotting method. This disorder leads to heavy and protracted bleeding after an injury. The bleeding process can also start on its own. Most of the types of bleeding disorders are hereditary but some are acquired due to liver diseases, side effects of certain medications, low red blood cell count, vitamin K deficiency and others. The bleeding disorders treatment market is expected to witness fast growth during the forecast period due to growth in the number of people suffering from liver diseases, anemia, and other blood coagulation disorders.


The bleeding disorders treatment market is seeing a rise due to growth in the number of diagnosed patients with bleeding disorders, rising research and development activities and investments by key players growth in awareness about bleeding disorders especially hemophilia and positive government initiatives in the developed countries towards establishing a wide network of diagnosis and treatment centers complementing the market growth. However, the absence of access to proper treatment due to the high cost of medication and the shortage of skilled health professionals hinders the growth of the market.


Segmentation


The bleeding disorders treatment market has been segmented on the basis of type, drug class, treatment and end users.


On the basis of type, the market has been classified as hemophilia A, hemophilia B, Von Willebrand Disease (vWD) and others.


On the basis of drug class, the market has been classified as plasma-derived coagulation factor concentrates market, global recombinant coagulation factor concentrate market, global others bleeding disorders treatment market.


On the basis of treatment, the market has been classified as desmopressin (DDAVP), hormone replacement therapy, contraceptives, anti-fibrinolytic/clot-stabilizing drugs, fibrin sealants, drugs applied to cuts and pipeline analysis (phase I, phase II and phase III clinical trials)


On the basis of end users, the market has been classified as hospitals, clinics, specialty clinics, research institutes, and others.


On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.


The European bleeding disorders treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The bleeding disorders treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The bleeding disorders treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.


Regional Market Summary


In the bleeding disorders treatment market, North America is anticipated to account for largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into drugs. According to the Hemophilia Federation of America, around 20,000 people are affected by hemophilia and approximately 1% of the population is suffering from Von Willebrand Disease (VWD).


The European market is expected to hold the second largest market share. Factors such as a rise in research expenses, advancement of technology, the decline in human health, and the necessity for innovative and effective therapies boost the growth of the market in this region. According to Statista, around 149,764 people were diagnosed with hemophilia A and about 10,811 people were diagnosed with other platelet disorders in the year 2016.


Whereas the market share in Asia-Pacific region is also anticipated to experience growth in the near future due to access to optimal treatment facilities and growing demand for increasing government initiatives, advanced technology, better adoption rate, and rising healthcare expenditure. According to the annual report survey of 2015 by the World Federation of Hemophilia, it is estimated that there were 17,346 million people suffering from hemophilia.


The market in the Middle East & Africa is expected to account for the smallest share of the bleeding disorders treatment market due to an underdeveloped healthcare sector, the dearth of technical knowledge, and poor medical facilities.


Key Players


Some of the key players in the bleeding disorders treatment market are Shire Plc, Bayer Pharmaceuticals, Novo Nordisk A/S, Pfizer Inc., Biogen Idec, CSL Behring, Grifols, Octapharma, Sun Pharmaceutical Industries Ltd., BDI Pharma, Ferring Pharmaceuticals, and others.


Bleeding Disorders Treatment Market, by Type



  • Hemophilia A

  • Hemophilia B

  • Von Willebrand Disease (vWD)

  • Others


Bleeding Disorders Treatment Market, by Drug Class



  • Plasma-derived coagulation factor concentrates market

  • Global recombinant coagulation factor concentrate market

  • Global others bleeding disorders treatment market


Bleeding Disorders Treatment Market, by Treatment



  • Medication

  • Desmopressin (DDAVP)

  • Hormone replacement therapy

  • Contraceptives

  • Anti-fibrinolytic/clot-stabilizing drugs

  • Fibrin sealants

  • Drugs applied to cuts

  • Pipeline analysis (phase I, phase II and phase III clinical trials)


Bleeding Disorders Treatment Market, by End-Users



  • Hospitals

  • Clinics

  • Research Institutes

  • Others


Bleeding Disorders Treatment Market, by Region



  • Americas

    • North America

    • US

    • Canada

    • South America



  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe



  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • Middle East & Africa

    • Middle East

    • Africa




Company Profiles



  • Shire Plc

  • Bayer Pharmaceuticals

  • Novo Nordisk A/S

  • Pfizer Inc.

  • Biogen Inc.

  • CSL Behring

  • Grifols

  • Octapharma

  • Sun Pharmaceutical Industries Ltd.

  • BDI Pharma

  • Ferring Pharmaceuticals

  • Others


Intended Audience



  • Manufacturers and distributors

  • Healthcare institutions (hospitals, laboratories, medical schools, and outpatient clinics)

  • Research institutes

  • Contract manufacturing organizations (CMOs)

  • Government associations

  • Market research and consulting firms

  • Venture capitalists and investors

Report Attribute/Metric Details
  Market Size   USD 29.8 Billion
  CAGR   10.7%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Drug class, Treatment and End users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Shire Plc, Bayer Pharmaceuticals, Novo Nordisk A/S, Pfizer Inc., Biogen Idec, CSL Behring, Grifols, Octapharma, Sun Pharmaceutical Industries Ltd., BDI Pharma, Ferring Pharmaceuticals, and others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers Growth in the number of diagnosed patients with bleeding disorders Rising research and development activities Growth in awareness about bleeding disorders


Frequently Asked Questions (FAQ) :

The bleeding disorders treatment market is projected to grow at a 10.7% CAGR between 2022-2030.

North America is projected to command the largest share in the bleeding disorders treatment market.

End users of bleeding disorders treatment market include specialty clinics, hospitals, clinics, and others.

Favorable compensation policies and increasing awareness may limit market growth.

High medication costs may limit market growth.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Request Free Sample
Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.
Ask for Customization